Movement Disorders

September 19, 2020

Neurology News Network for the week ending September 19, 2020.

September 18, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.

September 18, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers explained how social prescribing can play a key role in the prevention of social isolation.

September 17, 2020

The director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine gave his perspective on the interim findings of a long-term safety study of apomorphine sublingual film.

September 17, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

September 16, 2020

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

September 16, 2020

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

September 16, 2020

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.

September 16, 2020

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

September 15, 2020

The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.

September 15, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education and Clinical Centers discussed how loneliness can impact Parkinson disease severity and how holistic approaches to care may help.

September 15, 2020

Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.